Logo image of TLIS

TALIS BIOMEDICAL CORP (TLIS) Stock Fundamental Analysis

NASDAQ:TLIS - Nasdaq - US87424L2079 - Common Stock - Currency: USD

4.38  +0.22 (+5.29%)

After market: 4.49 +0.11 (+2.51%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TLIS. TLIS was compared to 190 industry peers in the Health Care Equipment & Supplies industry. While TLIS has a great health rating, there are worries on its profitability. While showing a medium growth rate, TLIS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TLIS had negative earnings in the past year.
TLIS had a negative operating cash flow in the past year.
TLIS had negative earnings in 4 of the past 5 years.
In the past 5 years TLIS always reported negative operating cash flow.
TLIS Yearly Net Income VS EBIT VS OCF VS FCFTLIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

TLIS's Return On Assets of -69.35% is on the low side compared to the rest of the industry. TLIS is outperformed by 77.78% of its industry peers.
TLIS has a Return On Equity of -100.93%. This is in the lower half of the industry: TLIS underperforms 67.20% of its industry peers.
Industry RankSector Rank
ROA -69.35%
ROE -100.93%
ROIC N/A
ROA(3y)-68.16%
ROA(5y)-29.58%
ROE(3y)-86.99%
ROE(5y)-37.77%
ROIC(3y)N/A
ROIC(5y)N/A
TLIS Yearly ROA, ROE, ROICTLIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

TLIS has a better Gross Margin (97.27%) than 100.00% of its industry peers.
TLIS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLIS Yearly Profit, Operating, Gross MarginsTLIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1K -2K

More info and screens

7

2. Health

2.1 Basic Checks

TLIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLIS has been increased compared to 1 year ago.
The number of shares outstanding for TLIS has been increased compared to 5 years ago.
There is no outstanding debt for TLIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TLIS Yearly Shares OutstandingTLIS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
TLIS Yearly Total Debt VS Total AssetsTLIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

TLIS has an Altman-Z score of -10.46. This is a bad value and indicates that TLIS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TLIS (-10.46) is worse than 82.01% of its industry peers.
There is no outstanding debt for TLIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.46
ROIC/WACCN/A
WACC8.69%
TLIS Yearly LT Debt VS Equity VS FCFTLIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

TLIS has a Current Ratio of 7.51. This indicates that TLIS is financially healthy and has no problem in meeting its short term obligations.
TLIS has a better Current ratio (7.51) than 84.66% of its industry peers.
A Quick Ratio of 7.51 indicates that TLIS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.51, TLIS belongs to the top of the industry, outperforming 88.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.51
Quick Ratio 7.51
TLIS Yearly Current Assets VS Current LiabilitesTLIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

TLIS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.72%, which is quite impressive.
Looking at the last year, TLIS shows a very negative growth in Revenue. The Revenue has decreased by -65.21% in the last year.
TLIS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.24% yearly.
EPS 1Y (TTM)42.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.28%
Revenue 1Y (TTM)-65.21%
Revenue growth 3Y-42%
Revenue growth 5Y-2.24%
Sales Q2Q%-93.25%

3.2 Future

The Earnings Per Share is expected to grow by 6.67% on average over the next years.
The Revenue is expected to grow by 154.95% on average over the next years. This is a very strong growth
EPS Next Y27.62%
EPS Next 2Y6.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y154.95%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TLIS Yearly Revenue VS EstimatesTLIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
TLIS Yearly EPS VS EstimatesTLIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TLIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLIS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLIS Price Earnings VS Forward Price EarningsTLIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLIS Per share dataTLIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TLIS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TALIS BIOMEDICAL CORP

NASDAQ:TLIS (8/30/2024, 8:26:04 PM)

After market: 4.49 +0.11 (+2.51%)

4.38

+0.22 (+5.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2024-08-07/amc
Earnings (Next)11-12 2024-11-12/amc
Inst Owners21.86%
Inst Owner Change-100%
Ins Owners18.29%
Ins Owner Change0%
Market Cap7.97M
Analysts36.67
Price Target5.1 (16.44%)
Short Float %0.34%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.06
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-31.43
EYN/A
EPS(NY)-28.34
Fwd EYN/A
FCF(TTM)-23.99
FCFYN/A
OCF(TTM)-23.74
OCFYN/A
SpS0.54
BVpS31.15
TBVpS31.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.35%
ROE -100.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.27%
FCFM N/A
ROA(3y)-68.16%
ROA(5y)-29.58%
ROE(3y)-86.99%
ROE(5y)-37.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.85%
Cap/Sales 46.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.51
Quick Ratio 7.51
Altman-Z -10.46
F-Score4
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)87.68%
Cap/Depr(5y)283.5%
Cap/Sales(3y)30.44%
Cap/Sales(5y)36.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.28%
EPS Next Y27.62%
EPS Next 2Y6.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-65.21%
Revenue growth 3Y-42%
Revenue growth 5Y-2.24%
Sales Q2Q%-93.25%
Revenue Next Year-100%
Revenue Next 2Y154.95%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.58%
OCF growth 3YN/A
OCF growth 5YN/A